Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study

被引：0

作者：

Mauro, Michael ^{[1
]}

Hochhaus, Andreas ^{[2
]}

Hughes, Timothy ^{[3
,4
]}

Rea, Delphine ^{[5
]}

Boquimpani, Carla ^{[6
]}

Minami, Yosuke ^{[7
]}

Apperley, Jane ^{[8
]}

Garcia-Gutierrez, Valentin ^{[9
]}

Kapoor, Shruti ^{[10
]}

Espurz, Noemi ^{[11
]}

Dhamal, Vishal ^{[12
]}

Cortes, Jorge ^{[13
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Univ Klinikum Jena, Jena, Germany

[3] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[4] Univ Adelaide, Adelaide, SA, Australia

[5] Hop St Louis, Paris, France

[6] State Inst Hematol Arthur Siquiera Cavalcanti, HEMORIO, Rio De Janeiro, Brazil

[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[8] Ctr Haematol Imperial Coll London, London, England

[9] Hosp Univ Ramon & Cajal IRYCIS, Serv Hematol, Madrid, Spain

[10] Novartis Pharmaceut, E Hanover, NJ USA

[11] Novartis Pharma AG, Basel, Switzerland

[12] Novartis Healthcare Private Ltd, Hyderabad, India

[13] Georgia Canc Ctr, Augusta, GA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

CML; asciminib; TKI; ASCEMBL; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-398

引用

页码：S340 / S340

页数：1

共 50 条

[1] Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After.2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update
Rea, Delphine
Hochhaus, Andreas
Mauro, Michael J.
Minami, Yosuke
Lomaia, Elza
Voloshin, Sergey
Turkina, Anna
Kim, Wook
Apperley, Jane F.
Cortes, Jorge E.
Abdo, Andre
Fogliatto, Laura Marie
Kim, Dennis Dong Hwan
le Coutre, Philipp
Saussele, Susanne
Annunziata, Mario
Hughes, Timothy P.
Chaudhri, Naeem
Chee, Lynette
Garcia-Gutierrez, Valentin
Sasaki, Koji
Kapoor, Shruti
Allepuz, Alex
Quenet, Sara
Bedoucha, Veronique
Boquimpani, Carla
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S295 - S296
[2] Trial in Progress: A Phase III Study of Asciminib vs an Investigator-Selected Tyrosine Kinase Inhibitor (TKI) in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Hughes, Timothy P.
Cortes, Jorge
Takahashi, Naoto
Larson, Richard
Issa, Ghayas C.
Bombaci, Felice
Ramscar, Nicholas
Kapoor, Shruti
Ifrah, Sophie
Hochhaus, Andreas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S297 - S298
[3] Tolerability of Asciminib vs Investigator-Selected (IS) Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 ASC4FIRST Study in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Issa, Ghayas C.
Larson, Richard A.
Hughes, Timothy P.
Hochhaus, Andreas
Takahashi, Naoto
Bombaci, Felice
Wang, Jianxiang
Kim, Dong-Wook
Dong, Dennis
Kim, Hwan
Gu, Ennan
Zhang, Yifan
Kapoor, Shruti
Agrawal, Nithya
Jinwal, Rajendra
Damon, Andrea
Sadek, Islam
Cortes, Jorge E.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S368 - S368
[4] Efficacy and Safety of Asciminib in Heavily Pretreated Patients with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Sensitivity to Tyrosine Kinase Inhibitors (TKIs)
Hughes, Timothy
Mauro, Michael
Kim, Dong-Wook
Cortes, Jorge
Rea, Delphine
Minami, Hironobu
Breccia, Massimo
DeAngelo, Daniel
Hochhaus, Andreas
Goh, Yeow-Tee
le Coutre, Philipp
Lang, Fabian
Cacciatore, Silvia
Aimone, Paola
Stenson, Laura
Polydoros, Fotis
Talpaz, Moshe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S235 - S235
[5] Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial
Smith, B. Douglas
Cortes, Jorge E.
Rea, Delphine
Mauro, Michael J.
Patwardhan, Pallavi
Maegawa, Rodrigo
Zacker, Christopher
Corbin, Regina
Keeping, Sam
Sasaki, Koji
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S334 - S334
[6] Matching-Adjusted Indirect Comparisons (MAICs) of Asciminib vs Other Tyrosine Kinase Inhibitors (TKIs) in Third- or Later-Line Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Atallah, Ehab
Jadhav, Kejal
Kangappaden, Teresa
Damon, Andrea
Samjoo, Imtiaz
Wei, David
Bhattacharyya, Devarshi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S337 - S337
[7] Asciminib After One Prior Tyrosine Kinase Inhibitor (TKI) in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Real-World Chart Review Study in the United States (US)
Atallah, Ehab L.
Sadek, Islam
Wei, David
Latremouille-Viau, Dominick
Rossi, Carmine
Damon, Andrea
Yang, Daisy
Bellefleur, Remi
Guerin, Annie
Jadhav, Kejal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S365 - S365
[8] A Multicenter, Randomized Phase 3 Study of Asciminib (ABL001) vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 TKIs
Mauro, Michael J.
Hochhaus, Andreas
Boquimpani, Carla
Minami, Yosuke
Allepuz, Alex
Polydoros, Fotis
Bedoucha, Veronique
Aimone, Paola
Rea, Delphine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S286 - S287
[9] ASCEMBL Phase 3 Health-Related Quality of Life (HRQL) Comparison of Asciminib and Bosutinib for Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or More Tyrosine Kinase Inhibitors (TKI)
Mauro, Michael J.
Boquimpani, Carla
Rea, Delphine
Hochhaus, Andreas
Maheshwari, Vikalp Kumar
Allepuz, Alex
Patwardhan, Pallavi
Wu, Ying
DeRosa, Michael
Minami, Yosuke
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S336 - S336
[10] Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US)
Kota, Vamsi
Maegawa, Rodrigo
Latremouille-Viau, Dominick
Jadhav, Kejal
Rossi, Carmine
Guerin, Annie
Iorga, Serban
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S300 - S301

← 1 2 3 4 5 →